Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid 211-63, Jordan.
Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar; Department of Chemistry, Jordan University of Science and Technology, Irbid 22110, Jordan; Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha 2713, Qatar.
Crit Rev Oncol Hematol. 2022 Jun;174:103677. doi: 10.1016/j.critrevonc.2022.103677. Epub 2022 Apr 3.
Defeating cancer is the ultimate challenge and goal of oncologists, facing various obstacles along with finding effective anti-cancer therapies and understanding drug delivery mechanisms. Additionally, the translation of the experimental findings to the clinical outcomes such as specificity, delivery, toxicity, clearance, and bioavailability is another health concern. Nanomedicine is a branch of nanotechnology that has been drastically developed in the last decades. Due to the fact of various nanomaterial formulas, different nanomedicine drug delivery tactics have been developed as anti-cancer therapies. The most effective and less toxic approaches involved the active targeting drug delivery tactic, which relies on the recognition of the drug nanoparticle carriers and the cell surface marker. Accordingly, FDA approved such a group of nanomedicine drug delivery systems while other formulas are still under the clinical trial phases. Nanomedicine is showing a bright future in the treatment of cancer. Oncologists learned from cancer research the possible drug resistance that could be developed. Consequently, researchers need to be prepared for the possible adverse effect of the nanomedicine approach.
战胜癌症是肿瘤学家的终极挑战和目标,他们在寻找有效抗癌疗法和了解药物输送机制的同时,也面临着各种障碍。此外,将实验结果转化为临床结果,如特异性、传递、毒性、清除和生物利用度,也是另一个健康关注点。纳米医学是纳米技术的一个分支,在过去几十年中得到了迅猛发展。由于各种纳米材料配方的存在,已经开发出了不同的纳米医学药物输送策略作为抗癌疗法。最有效和毒性较小的方法涉及主动靶向药物输送策略,该策略依赖于对药物纳米颗粒载体和细胞表面标记物的识别。因此,FDA 批准了这样一组纳米医学药物输送系统,而其他配方仍处于临床试验阶段。纳米医学在癌症治疗方面展现出了光明的前景。肿瘤学家从癌症研究中了解到可能会产生的药物耐药性。因此,研究人员需要为纳米医学方法可能产生的不良反应做好准备。